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VEGF-C and VEGF-D have been implicated in lymphatic metastasis, mainly as inducers of new intra/peritu-
moral capillary lymphatics. In this issue of Cancer Cell, Karnezis and colleagues challenge this notion and
demonstrate that tumor-derived VEGF-D promotes metastasis by causing prostaglandin-dependent dilation
of collecting lymphatics outside of the tumor mass.Metastasis defines the progressive, sys-
temic, and intractable nature of late-stage
human cancers. Implicitly, this process
involves trafficking of cancer cells within
blood and lymphatic compartments to
sites of their secondary growth in distant
organs and regional lymph nodes, respec-
tively (Fidler, 2003). By extension, the cor-
responding processes of tumor-induced
formation of new blood vessels (angiogen-
esis) and lymphatics (lymphangiogenesis)
are often viewed as prerequisites for the
onset of hematogenous and lymphatic
dissemination. Either of the resulting mi-
crovascular networks may constitute a
point of entry for cancer cells into the
vascular system and a rate limiting step in
disease spreading (Folkman, 2007; Alitalo,
2011). In spite of some controversy as to
the causal role of lymph node metastases
as ‘‘launch pads’’ of systemic dissemina-
tion (Sleeman and Thiele, 2009), the in-
herent appeal of this possibility has con-
tributed to a growing interest in targeting
lymphangiogenesis as an early pro-meta-
static switch in cancer (Alitalo, 2011).
Much of the effort in this area has
centered around obliteration of major
lymphangiogenic growth factor pathways
triggeredbymembersof thevascularendo-
thelial growth factor (VEGF) family, espe-
ciallyVEGF-C,VEGF-D,and tosomeextent
VEGF-A, all of which may be expressed by
metastatic cancer cells. The respective
receptors for these factors, VEGFR3 and
VEGFR2, are present on lymphatic endo-
thelial cells (LECs), which can be distin-
guished from their vascular counterparts
by patterns of gene expression and distinct
molecularmarkers (LYVE-1,Prox1, andpo-
doplanin) (Alitalo, 2011). LECs line both the
terminal, thin walled lymphatics, devoid of
supporting mural cells, and their drainingcontractile ducts, collecting lymphatic
vessels (CLVs), which contain mural cells
and pass the interstitial fluid (and cancer
cells) to the regional lymph nodes.
Several specific monoclonal anti-
bodies, soluble receptors, and small mol-
ecule inhibitors have been developed
to block VEGF/VEGF receptor (VEGFR)
pathways and impede lymphangiogene-
sis. In addition, the expression of VEGFs
by cancer cells can be inhibited using
non-steroidal anti-inflammatory drugs
(NSAIDs) and other agents. The intuitively
obvious way to observe whether these
drugs actually work in cancer would be
to follow the expected decline in density
of capillary lymphatics within, and adja-
cent to, the tumor mass, using LEC
markers such as LYVE-1. Indeed, such
effects have been observed and may, at
least in some cases, be rate-limiting for
lymphatic and systemic metastasis.
As it turns out, clues as to the role of
VEGFs in lymph node metastasis may
also be found outside of the proverbial
‘‘box,’’ i.e., away from the tumor masses,
and within their draining CLVs. A compel-
ling example of this scenario is described
by Karnezis et al., (2012) in this issue of
Cancer Cell. These authors set out to
explore processes by which tumors
expressing VEGF-D trigger lymph node
metastasis. Although such tumors do
contain rich networks of capillary lym-
phatics, these investigators noticed that
what separated them from their non-meta-
static counterparts was a startling (macro-
scopic) enlargement of CLVs draining the
tumor basin to sentinel lymph nodes. The
striking images of this CLV dilation suggest
that the lymphatic influence of a growing
cancer is not confined to its physical
boundaries, but extends far beyond. WhatCancer Cell 21,might be the mechanism by which VEGF-
D-expressing tumor cells exert such
a long distance influence (over tens ofmilli-
meters), and what are the consequences?
In search for answers Karnezis et al.,
(2012) first documented that CVL dilation
is, indeed, directly VEGF-D-dependent.
For example, this effect was absent in the
case of non-metastic and VEGF-D non-ex-
pressing tumors or when VEGF-D was
replacedwithVEGF-A. Likewise, treatment
with neutralizing antibodies against
VEGF-D (VD1), VEGFR3 (mF4-31C1), or
VEGFR2 (DC101) abolished CLV dilation.
These observations suggest that VEGF-D
causesdilation throughcooperativeactiva-
tion of VEGFR3 and VEGFR2 in LECs that
are located in the extra-tumoral CLV
segments.Todetermine thenatureof these
responses, CLVs were isolated, and their
LEC populations were purified and profiled
for gene expression. This revealed a dis-
tinct molecular signature of these cells,
including their ability to markedly down-
regulate prostaglandin dehydrogenase
(PGDH) in the presence of VEGF-D.
PGDH breaks down prostaglandins (e.g.,
PGE2), thereby opposing the action of the
prostaglandin synthesis pathway driven
by cyclooxygenase 2. Thus, downregula-
tion of PGDH in LECs exposed to VEGF-D
raises the levels of circulating prostaglan-
dins, which in turn act on mural cells within
tumor-related CLVs, causing their dilation.
These events have profound conse-
quences for metastasis. Karnezis et al.,
(2012) demonstrated that essentially all
treatments that counteracted CLV dila-
tion also diminished the metastatic load
in draining lymph nodes. Interestingly,
Etodolac, an NSAID, triggers these ef-
fects essentially without changing the
lymphatic or blood vessel density withinFebruary 14, 2012 ª2012 Elsevier Inc. 139
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Previewsthe primary tumor, which suggests that
CLV dilation may have a far more central
role in the metastatic process than hith-
erto appreciated. Interestingly, Etodolac
also diminished metastatic burden in the
lung. These results suggest that a level
of control over the lymphatic and sys-
temic dissemination could potentially be
achieved by administration of relatively
safe anti-inflammatory agents.
This provocative study adds an impor-
tant dimension to the process that might
be viewed as vascular system ‘‘condi-
tioning’’ for cancer metastasis. While the
focus of the present study is on CLV dila-
tion, others observed lymphangiogenesis
within lymph nodes prior to their meta-
static colonization (Tobler and Detmar,
2006), a process that may be attributed
to remote influences of growth factors
or exosomes (Hood et al., 2011). Analo-
gous pre-metastatic niches were also
described at sites of blood borne metas-
tases (Kaplan et al., 2005).
The enlargement ofmacroscopic vessels
located outside of a growing tumor is not
restricted to CLVs. Similar increases in
diameter are often observed in the case of
bloodvessels thatsupply tumormicrocircu-
lation (feeding arteries and collecting veins),
which is also apparent from some of the
images included in the study by Karnezis
et al., (2012). Although this is a commonly
observed phenomenon, the underlying bio-
logical process has thus far attracted
minimal attention (Yu and Rak, 2003). In
contrast to angiogenesis, which occurs at
the level of microscopic capillaries (Carme-140 Cancer Cell 21, February 14, 2012 ª2012liet and Jain, 2011), formation of larger
tumor-feeding blood vessels may involve
such mechanisms as dilation, similar to
that occurring in CLVs, or circumferential
growth (‘‘tumor arteriogenesis’’) (Yu and
Rak, 2003). Whether such macroscopic
changes control tumor microenvironment,
growth, or hematogenous metastasis (by
analogy to CLVs) remains to be studied.
The novel and fascinating link between
CLV dilation and lymphatic metastasis
described by these authors raises several
important questions. For example, how
does CLV dilation promote metastasis? Is
this merely a wider conduit (‘‘plumbing’’)
effect, or does it involve more subtle regu-
latory mechanisms (e.g., tumor-LEC inter-
actions)? Since the VEGF-D-induced
increase in prostaglandin levels is detected
inperipheral blood, could suchachangebe
indicative of impending lymphatic metas-
tasis in the clinic? How early in progression
ofhumancancerswould increase inprosta-
glandins occur, and how discrete, how
detectable, would this event be? What
systemic consequences may be associ-
ated with VEGF-D-induced increase in
prostaglandins in blood, e.g., for the
vascular system? What turns on lymphan-
giogenic growth factors in metastatic
cancers, and is there a link between onco-
genic pathways and CLV dilation?
It is fascinating to think that a pharmaco-
logical blockade of the pathological CLV
dilation and metastasis could be achieved
with already available agents (VEGF/
VEGFR3/2 inhibitors and NSAIDs). How-
ever, onewonderswhether such treatmentElsevier Inc.could interfere with the lymph outflow from
the primary tumor mass leading to a build
up of interstitial fluid pressure (IFP)?
Increase in IFP has been linked to impaired
drug delivery and could result in vascular
compression, hypoxia, and perhaps in
hematogenous metastasis. It is unclear if
anyof theseeffectsmightaccompany ther-
apeutic interference with CLV dilation.
Indeed, the work of Karnezis et al., (2012)
opens up several new lines of inquiry
and a new domain in the field of lymphan-
giogenesis and cancer progression.REFERENCES
Fidler, I.J. (2003). Nat. Rev. Cancer 3, 453–458.
Folkman,J. (2007).Nat.Rev.DrugDiscov.6, 273–286.
Alitalo, K. (2011). Nat. Med. 17, 1371–1380.
Sleeman, J.P., and Thiele, W. (2009). Int. J. Cancer
125, 2747–2756.
Karnezis, T., Shayan, R., Ceasar, C., Roufail, S.,
Harris, N.C., Ardipradja, K., Zhang, Y.F., Williams,
S.P., Farnsworth, R.H., Chai, M.G., et al. (2012).
Cancer Cell 21, this issue, 181–195.
Tobler, N.E., and Detmar, M. (2006). J. Leukoc.
Biol. 80, 691–696.
Hood, J.L., San, R.S., and Wickline, S.A. (2011).
Cancer Res. 71, 3792–3801.
Kaplan, R.N., Riba, R.D., Zacharoulis, S., Bramley,
A.H., Vincent, L., Costa, C., MacDonald, D.D., Jin,
D.K., Shido, K., Kerns, S.A., et al. (2005). Nature
438, 820–827.
Yu, J.L., and Rak, J.W. (2003). Breast Cancer Res.
5, 83–88.
Carmeliet, P., and Jain, R.K. (2011). Nature 473,
298–307.aSIRTing Control over Cancer Stem CellsTakahiro Ito,1 Bryan Zimdahl,1,2 and Tannishtha Reya1,*
1Department of Pharmacology, University of California San Diego School of Medicine, La Jolla, CA 92093, USA
2Department of Pharmacology and Cancer Biology, Duke University Medical Center, Durham, NC 27710, USA
*Correspondence: treya@ucsd.edu
DOI 10.1016/j.ccr.2012.01.014
Cancer stem cells lie at the root of chronic myelogenous leukemia (CML) and mediate its continued growth.
Their resistance to current therapies results in an inability to eradicate the disease. In this issue ofCancer Cell,
Li et al. identify SIRT1 as a new target for eliminating CML cancer stem cells.Chronic myelogenous leukemia (CML) is
a cancer that begins in hematopoieticstem cells. Triggered by the BCR-ABL
translocation (Melo and Barnes, 2007),additional mutations can induce its
progression from a slow-growing chronic
